Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;45(10):3157-3164.
doi: 10.1007/s00268-021-06209-x. Epub 2021 Jul 8.

Ovarian Metastasis from Pancreatic Ductal Adenocarcinoma

Joseph R Habib  1 , Shamsher Pasha  1 , Subhan Khan  1 , Benedict Kinny-Köster  1 , Sami Shoucair  1 , Elizabeth D Thompson  2 , Jun Yu  1 , Kelly Lafaro  1 , Richard A Burkhart  1 , William R Burns  1 , Brigitte M Ronnett  2 , Christopher L Wolfgang  3 , Ralph H Hruban  2 , Jin He  1 , Elliot K Fishman #  4 , Ammar A Javed #  5
Affiliations

Ovarian Metastasis from Pancreatic Ductal Adenocarcinoma

Joseph R Habib et al. World J Surg. 2021 Oct.

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) has a high propensity for systemic dissemination. Ovarian metastases are rare and poorly described.

Methods: We identified PDAC cases with ovarian metastasis from a prospectively maintained registry. We reported on the association between outcomes and clinicopathologic factors. Recurrence-free (RFS) and overall survival (OS) were calculated using Kaplan-Meier analysis.

Results: Twelve patients with PDAC and synchronous or metachronous ovarian metastases were identified. Nine patients (75%) underwent pancreatectomy for localized PDAC and developed metachronous ovarian recurrence. The median OS for all patients was 25.4 (IQR:15.4-82.9) months. For the nine patients with metachronous ovarian metastasis, the median RFS and OS were 14.2 (IQR:7.2-58.3) and 44.6 (IQR:18.6-82.9) months, respectively. Nodal disease, poor grade, vascular invasion in the pancreatic primary, and bilateral ovarian disease tended to confer worse outcomes.

Conclusion: Patients with resected PDAC and ovarian recurrence tend to have a comparable disease course to more common patterns of recurrence. Primaries with nodal disease, poorer grade, vascular invasion, and bilateral ovarian disease were indicative of more aggressive disease biology. The ideal management remains largely unknown, and future collaborative efforts should optimize therapeutic strategies.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7–33 - DOI
    1. Lennon AM, Wolfgang CL, Canto MI et al (2014) The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res 74(13):3381–3389 - DOI
    1. Hruban RH, Gaida MM, Thompson E et al (2019) Why is pancreatic cancer so deadly? The Pathologist’s View J Pathol 248(2):131–141 - PubMed
    1. Groot VP, Rezaee N, Wu W et al (2018) Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg 267(5):936–945 - DOI
    1. Habib JR, Kinny-Köster B, Bou-Samra P et al (2021) Surgical decision making in pancreatic ductal adenocarcinoma: modeling prognosis following pancreatectomy in the era of induction and neoadjuvant chemotherapy. Ann Surg. https://doi.org/10.1097/SLA.0000000000004915 (published online ahead of print, 2021 Apr 9) - DOI - PubMed

Publication types